HRSA on Monday released a letter to each of the six pharmaceutical manufacturers — Eli Lilly, AstraZeneca, Novo Nordisk, Novartis, Sanofi, United Therapeutics – that have placed restrictions on deliveries to contract pharmacies, stating those restrictions are in violation of the 340B statute. Using the same interpretation of the 340B statute as the earlier advisory opinion, HRSA ordered the manufacturers to immediately resume offering 340B drugs to contract pharmacies. Failure to do so could result in a fine up to $5,000 per instance, along with a refund of any overcharge. HRSA asked the manufacturers to provide a compliance status update by June 1. NCPA continues to advocate for polices that protect independent pharmacies participating in the 340B program.